Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Envelope Protein gp120 | 30 | 2023 | 947 | 3.260 |
Why?
|
HIV-1 | 39 | 2023 | 6931 | 1.810 |
Why?
|
HIV Antibodies | 12 | 2023 | 1309 | 1.310 |
Why?
|
HIV Fusion Inhibitors | 8 | 2022 | 83 | 1.250 |
Why?
|
Molecular Mimicry | 8 | 2023 | 203 | 1.090 |
Why?
|
HIV Envelope Protein gp41 | 11 | 2022 | 315 | 1.030 |
Why?
|
Virus Internalization | 12 | 2023 | 499 | 0.990 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 6 | 2022 | 363 | 0.980 |
Why?
|
HIV Infections | 24 | 2023 | 16764 | 0.970 |
Why?
|
Middle East | 7 | 2023 | 219 | 0.970 |
Why?
|
Indenes | 2 | 2022 | 57 | 0.820 |
Why?
|
Guanidines | 2 | 2022 | 191 | 0.810 |
Why?
|
Biomimetics | 4 | 2020 | 171 | 0.790 |
Why?
|
AIDS Vaccines | 3 | 2018 | 924 | 0.730 |
Why?
|
Anti-HIV Agents | 17 | 2023 | 4320 | 0.720 |
Why?
|
Antibodies, Neutralizing | 7 | 2020 | 1957 | 0.700 |
Why?
|
Lentiviruses, Primate | 1 | 2018 | 7 | 0.660 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2017 | 2241 | 0.650 |
Why?
|
Protein Multimerization | 5 | 2019 | 970 | 0.640 |
Why?
|
Africa, Northern | 5 | 2020 | 82 | 0.640 |
Why?
|
Harm Reduction | 1 | 2016 | 126 | 0.510 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1779 | 0.480 |
Why?
|
Piperazines | 7 | 2020 | 2480 | 0.460 |
Why?
|
Epidemics | 2 | 2016 | 520 | 0.440 |
Why?
|
Receptors, CXCR4 | 8 | 2012 | 726 | 0.390 |
Why?
|
Substance Abuse, Intravenous | 1 | 2016 | 523 | 0.390 |
Why?
|
Receptors, CCR5 | 7 | 2019 | 497 | 0.380 |
Why?
|
Culture | 1 | 2014 | 627 | 0.360 |
Why?
|
Iran | 3 | 2018 | 700 | 0.340 |
Why?
|
Receptors, HIV | 3 | 2023 | 162 | 0.330 |
Why?
|
Membrane Fusion | 3 | 2010 | 271 | 0.320 |
Why?
|
Drug Resistance, Viral | 2 | 2022 | 829 | 0.320 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 3 | 2023 | 301 | 0.300 |
Why?
|
Phenylalanine | 3 | 2020 | 365 | 0.290 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 2006 | 39 | 0.290 |
Why?
|
Ethers | 1 | 2006 | 74 | 0.280 |
Why?
|
International Cooperation | 1 | 2013 | 1420 | 0.280 |
Why?
|
Hepatitis C | 1 | 2016 | 1580 | 0.270 |
Why?
|
Gene Products, env | 1 | 2006 | 263 | 0.260 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5272 | 0.260 |
Why?
|
Health Personnel | 1 | 2018 | 3203 | 0.250 |
Why?
|
Protein Conformation | 12 | 2022 | 4012 | 0.250 |
Why?
|
HEK293 Cells | 9 | 2020 | 4174 | 0.240 |
Why?
|
Women's Health | 1 | 2014 | 2029 | 0.240 |
Why?
|
Immunization | 3 | 2018 | 1255 | 0.240 |
Why?
|
Cell Line | 16 | 2020 | 15987 | 0.240 |
Why?
|
Triazoles | 3 | 2017 | 906 | 0.230 |
Why?
|
Glycoproteins | 2 | 2022 | 2259 | 0.230 |
Why?
|
Neutralization Tests | 6 | 2017 | 757 | 0.220 |
Why?
|
Gene Products, vif | 1 | 2002 | 33 | 0.220 |
Why?
|
Antiviral Agents | 2 | 2019 | 2971 | 0.220 |
Why?
|
Protein Binding | 14 | 2023 | 9375 | 0.220 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3138 | 0.210 |
Why?
|
Virus Attachment | 3 | 2011 | 55 | 0.210 |
Why?
|
Antigens, Nuclear | 1 | 2002 | 192 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3143 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3248 | 0.210 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5128 | 0.190 |
Why?
|
Dogs | 6 | 2020 | 3915 | 0.190 |
Why?
|
Models, Molecular | 10 | 2020 | 5460 | 0.190 |
Why?
|
Amino Acid Substitution | 4 | 2017 | 1793 | 0.180 |
Why?
|
Thermodynamics | 4 | 2012 | 594 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8274 | 0.180 |
Why?
|
Inhibitory Concentration 50 | 2 | 2017 | 464 | 0.160 |
Why?
|
Administration, Intravaginal | 1 | 2018 | 147 | 0.160 |
Why?
|
Humans | 56 | 2023 | 739398 | 0.160 |
Why?
|
Chemokines | 3 | 2007 | 948 | 0.160 |
Why?
|
Binding Sites | 8 | 2023 | 6113 | 0.160 |
Why?
|
Calorimetry | 4 | 2012 | 125 | 0.160 |
Why?
|
Drug Design | 4 | 2014 | 1088 | 0.150 |
Why?
|
Giant Cells | 2 | 2017 | 187 | 0.150 |
Why?
|
Viral Envelope Proteins | 2 | 2016 | 635 | 0.150 |
Why?
|
HIV Seropositivity | 1 | 2023 | 966 | 0.150 |
Why?
|
Sindbis Virus | 1 | 2016 | 36 | 0.150 |
Why?
|
Macaca mulatta | 3 | 2018 | 2384 | 0.150 |
Why?
|
Receptors, Virus | 3 | 2011 | 648 | 0.140 |
Why?
|
Morocco | 1 | 2016 | 28 | 0.140 |
Why?
|
Developed Countries | 2 | 2017 | 433 | 0.140 |
Why?
|
Peptide Fragments | 4 | 2016 | 5076 | 0.140 |
Why?
|
Structure-Activity Relationship | 8 | 2017 | 3146 | 0.140 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2020 | 4374 | 0.130 |
Why?
|
Haplorhini | 1 | 2016 | 558 | 0.130 |
Why?
|
Human Rights | 1 | 2018 | 303 | 0.130 |
Why?
|
Pyridones | 1 | 2019 | 707 | 0.130 |
Why?
|
Drug and Narcotic Control | 1 | 2016 | 146 | 0.130 |
Why?
|
Drug Discovery | 2 | 2020 | 1056 | 0.130 |
Why?
|
Small Molecule Libraries | 2 | 2017 | 728 | 0.120 |
Why?
|
Epitopes | 3 | 2017 | 2558 | 0.120 |
Why?
|
Peptides | 3 | 2012 | 4395 | 0.120 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 473 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 545 | 0.120 |
Why?
|
Lentivirus | 1 | 2016 | 501 | 0.120 |
Why?
|
Chemokine CXCL12 | 3 | 2011 | 462 | 0.120 |
Why?
|
Thymus Gland | 1 | 2018 | 1263 | 0.110 |
Why?
|
Microbial Sensitivity Tests | 2 | 2017 | 1866 | 0.110 |
Why?
|
Protein Folding | 1 | 2017 | 842 | 0.110 |
Why?
|
Mice, SCID | 1 | 2018 | 2716 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1374 | 0.110 |
Why?
|
Virus Uncoating | 1 | 2012 | 13 | 0.110 |
Why?
|
Animals | 15 | 2020 | 168368 | 0.100 |
Why?
|
Social Stigma | 1 | 2018 | 695 | 0.100 |
Why?
|
Policy Making | 1 | 2016 | 554 | 0.100 |
Why?
|
Indans | 1 | 2012 | 96 | 0.100 |
Why?
|
Drug Users | 1 | 2013 | 132 | 0.100 |
Why?
|
Risk | 1 | 2023 | 9684 | 0.100 |
Why?
|
Chemokines, CC | 1 | 2011 | 291 | 0.090 |
Why?
|
Proteolipids | 1 | 2010 | 117 | 0.090 |
Why?
|
Oxalates | 2 | 2011 | 104 | 0.090 |
Why?
|
Sulfonamides | 1 | 2019 | 1934 | 0.090 |
Why?
|
Hydrocarbons | 1 | 2010 | 100 | 0.090 |
Why?
|
Cytopathogenic Effect, Viral | 2 | 2006 | 156 | 0.090 |
Why?
|
Virus Replication | 4 | 2019 | 2529 | 0.090 |
Why?
|
Capsid Proteins | 1 | 2012 | 479 | 0.080 |
Why?
|
Ligands | 5 | 2020 | 3311 | 0.080 |
Why?
|
Bone Marrow | 1 | 2018 | 2933 | 0.080 |
Why?
|
Liposomes | 1 | 2011 | 760 | 0.080 |
Why?
|
Mutation | 4 | 2022 | 29658 | 0.080 |
Why?
|
Rabbits | 1 | 2014 | 4882 | 0.080 |
Why?
|
Program Evaluation | 1 | 2016 | 2484 | 0.070 |
Why?
|
Antibodies, Viral | 1 | 2018 | 3151 | 0.070 |
Why?
|
Recombinant Proteins | 3 | 2015 | 6610 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2013 | 1331 | 0.070 |
Why?
|
Crystallography, X-Ray | 3 | 2017 | 2015 | 0.070 |
Why?
|
Conserved Sequence | 1 | 2008 | 1203 | 0.060 |
Why?
|
Hot Temperature | 1 | 2010 | 1358 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3844 | 0.060 |
Why?
|
Crystallization | 2 | 2020 | 528 | 0.060 |
Why?
|
Molecular Weight | 1 | 2006 | 2257 | 0.060 |
Why?
|
Stereoisomerism | 2 | 2019 | 628 | 0.060 |
Why?
|
HIV | 2 | 2011 | 1607 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3908 | 0.060 |
Why?
|
Female | 7 | 2018 | 378853 | 0.060 |
Why?
|
Protein Structure, Tertiary | 3 | 2006 | 3848 | 0.060 |
Why?
|
Amino Acids | 2 | 2007 | 1727 | 0.060 |
Why?
|
vif Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 53 | 0.050 |
Why?
|
Transcription Factors | 1 | 2002 | 12120 | 0.050 |
Why?
|
Binding, Competitive | 3 | 2011 | 1158 | 0.050 |
Why?
|
Liver | 1 | 2018 | 7449 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2006 | 669 | 0.050 |
Why?
|
U937 Cells | 1 | 2002 | 267 | 0.050 |
Why?
|
Piperidines | 2 | 2011 | 1597 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2018 | 18003 | 0.050 |
Why?
|
Antibodies, Monoclonal | 3 | 2016 | 9259 | 0.050 |
Why?
|
HL-60 Cells | 1 | 2002 | 361 | 0.050 |
Why?
|
Databases, Factual | 1 | 2017 | 7690 | 0.050 |
Why?
|
Jurkat Cells | 1 | 2002 | 740 | 0.050 |
Why?
|
Molecular Conformation | 2 | 2014 | 565 | 0.040 |
Why?
|
Phenotype | 1 | 2017 | 16301 | 0.040 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2015 | 1721 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15153 | 0.040 |
Why?
|
Health Care Sector | 1 | 2020 | 194 | 0.040 |
Why?
|
Mutagenesis | 1 | 2002 | 1265 | 0.040 |
Why?
|
Glutaral | 1 | 2018 | 78 | 0.040 |
Why?
|
Oligopeptides | 1 | 2004 | 1179 | 0.040 |
Why?
|
Time Factors | 2 | 2020 | 40050 | 0.040 |
Why?
|
Surface Plasmon Resonance | 2 | 2012 | 275 | 0.040 |
Why?
|
Health Priorities | 1 | 2020 | 380 | 0.040 |
Why?
|
Amino Acid Sequence | 4 | 2016 | 13816 | 0.040 |
Why?
|
Antigenic Variation | 1 | 2016 | 125 | 0.030 |
Why?
|
HeLa Cells | 1 | 2002 | 3119 | 0.030 |
Why?
|
Antibodies, Blocking | 1 | 2016 | 254 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2016 | 5959 | 0.030 |
Why?
|
Urea | 1 | 2017 | 448 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2017 | 500 | 0.030 |
Why?
|
Male | 3 | 2018 | 349022 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6310 | 0.030 |
Why?
|
Drug Industry | 1 | 2020 | 742 | 0.030 |
Why?
|
Lymphocytes | 1 | 2002 | 2612 | 0.030 |
Why?
|
Risk Assessment | 1 | 2016 | 23294 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2017 | 940 | 0.030 |
Why?
|
Chemokines, CXC | 2 | 2005 | 422 | 0.030 |
Why?
|
Cold Temperature | 1 | 2017 | 775 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2016 | 916 | 0.030 |
Why?
|
Gene Targeting | 1 | 2016 | 886 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 25470 | 0.030 |
Why?
|
Reverse Transcription | 1 | 2012 | 46 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2018 | 62693 | 0.030 |
Why?
|
Genetic Vectors | 2 | 2016 | 3419 | 0.030 |
Why?
|
Protein Structure, Quaternary | 1 | 2012 | 437 | 0.020 |
Why?
|
Protein Denaturation | 1 | 2010 | 237 | 0.020 |
Why?
|
Biological Availability | 1 | 2010 | 390 | 0.020 |
Why?
|
Molecular Dynamics Simulation | 1 | 2012 | 409 | 0.020 |
Why?
|
Health Services Research | 1 | 2017 | 1832 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 71974 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2006 | 18125 | 0.020 |
Why?
|
COS Cells | 1 | 2009 | 1159 | 0.020 |
Why?
|
Simian immunodeficiency virus | 1 | 2012 | 846 | 0.020 |
Why?
|
Circular Dichroism | 1 | 2006 | 354 | 0.020 |
Why?
|
Radioligand Assay | 1 | 2005 | 379 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2014 | 1476 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2012 | 2200 | 0.020 |
Why?
|
Kinetics | 1 | 2012 | 6475 | 0.020 |
Why?
|
Epitope Mapping | 1 | 2005 | 312 | 0.020 |
Why?
|
Binding Sites, Antibody | 1 | 2004 | 349 | 0.010 |
Why?
|
HIV Envelope Protein gp160 | 1 | 2003 | 99 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7788 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2005 | 1096 | 0.010 |
Why?
|
Computer Simulation | 1 | 2016 | 6237 | 0.010 |
Why?
|
Biocompatible Materials | 1 | 2011 | 1730 | 0.010 |
Why?
|
Signal Transduction | 3 | 2012 | 23355 | 0.010 |
Why?
|
Molecular Structure | 1 | 2007 | 1925 | 0.010 |
Why?
|
Allosteric Regulation | 1 | 2004 | 407 | 0.010 |
Why?
|
Temperature | 1 | 2009 | 2202 | 0.010 |
Why?
|
Solubility | 1 | 2004 | 1083 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2012 | 3757 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16646 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2005 | 2256 | 0.010 |
Why?
|
Stromal Cells | 1 | 2005 | 1350 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2009 | 2552 | 0.010 |
Why?
|
Cell Death | 1 | 2003 | 1693 | 0.010 |
Why?
|
Genetic Variation | 1 | 2011 | 6539 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 5742 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2003 | 19220 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 2004 | 10142 | 0.000 |
Why?
|
Mice | 1 | 2011 | 81002 | 0.000 |
Why?
|
Concepts
(215)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_